Cue Biopharma (NASDAQ:CUE) Stock: Insider Michael Vincent Meluzio Sells 1,144 Shares

Cue Biopharma, Inc. (NASDAQ:CUE) VP Michael Vincent Meluzio sold 1,144 shares of the stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $28.05, for a total transaction of $32,089.20. Following the sale, the vice president owned 47,817 shares in the company, valued at $1,341,266.85. The trade was a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Vincent Meluzio also recently made the following trade(s):

• On Thursday, August 13th, Michael Vincent Meluzio sold 5,628 shares of Cue Biopharma stock. The stock was sold at an average price of $30.09, for a total value of $169,346.52.

Cue Biopharma Price Performance

NASDAQ:CUE traded down $0.97 during trading hours on Wednesday, hitting $18.60. The company’s stock had a trading volume of 244,958 shares, compared to its average volume of 475,854. The stock has a fifty day simple moving average of $27.73 and a 200-day simple moving average of $72.25. The company has a market capitalization of $135.04 million, a P/E ratio of -0.69 and a beta of 2.62. Cue Biopharma, Inc. has a twelve month low of $4.97 and a twelve month high of $45.50.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The company had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. On average, equities analysts predict that Cue Biopharma, Inc. will post -21.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CUE has been the topic of a number of research reports. B. Riley Financial started coverage on shares of Cue Biopharma in a research note on Friday, September 18th. They set a “buy” rating and a $83.00 target price on the stock. Wall Street Zen cut Cue Biopharma from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 26th. Weiss Ratings cut Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. Finally, Zacks Research raised Cue Biopharma to a “hold” rating in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Cue Biopharma presently has an average rating of “Hold” and an average target price of $83.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC boosted its position in Cue Biopharma by 301.8% during the second quarter. Citadel Advisors LLC now owns 25,633 shares of the company’s stock valued at $809,000 after acquiring an additional 38,333 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in Cue Biopharma in the second quarter valued at approximately $338,000. Bank of America Corp DE acquired a new stake in Cue Biopharma in the 2nd quarter valued at $219,000. ADAR1 Capital Management LLC bought a new stake in shares of Cue Biopharma during the second quarter worth about $1,742,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Cue Biopharma during the 2nd quarter worth approximately $83,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.